Can a simple pill prevent deadly clots in lung cancer patients?
NCT ID NCT07160686
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether the blood thinner apixaban can prevent dangerous blood clots in people with lung cancer who are receiving chemotherapy or similar treatments. About 1,456 participants will take either apixaban or a placebo twice a day for six months. The goal is to see if apixaban reduces the number of clots without causing serious bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apixaban (a blood thinner)
What this could lead to
If it works, this could provide a safe way to prevent blood clots in lung cancer patients, reducing hospitalizations and deaths from clots.
What could go wrong
This is a large phase 3 trial, but blood thinners carry a risk of bleeding. The benefit may not outweigh the risk for all patients, and results may not apply to other cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Birmingham
Birmingham, B15 2TT, United Kingdom